Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

ADAMTS13, RECOMBINANT-KRHN: Who Reports Side Effects? Age, Gender & Country Data

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

Gender Distribution

60.7%
Female
39.3%
Male

Age Information

The average age of patients reporting adverse events with ADAMTS13, RECOMBINANT-KRHN is 27.6 years.

Geographic Distribution

The majority of adverse event reports for ADAMTS13, RECOMBINANT-KRHN originate from US.

Report Summary & Outcomes

68
Total Reports
68
As Primary/Secondary Suspect
1
Deaths Reported
20
Hospitalizations
1
Life-Threatening

Reporting Timeline

First adverse event report: 20221201. Most recent report: 20250712. View full timeline →

More About ADAMTS13, RECOMBINANT-KRHN

ADAMTS13, RECOMBINANT-KRHN Full Profile Reports by Year Drug Interactions